Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers

NCT04939467 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Drug Drug Interaction

Interventions

DRUG: Pirfenidone 267 mg Oral Tablet
DRUG: Nintedanib 150 mg Oral Capsule
DRUG: BLD-0409 750 mg Oral Tablet

Sponsor

Blade Therapeutics